The effect of Myoinositol on the outcomes of assisted reproductive treatments in patients with polycystic ovary syndrome

Comparison of the effect of Myoinositol with the control group on the outcomes of assisted reproductive treatments in patients with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240119060732N2

Enrollment

Registered

2024-06-29

Start date

2024-08-22

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female infertility associated with anovulation. Female infertility associated with anovulation

Interventions

Intervention 1: Intervention group: They receive myoinositol powder 4 grams per day for 8 weeks and then enter the ovulation cycle. Intervention 2: Control group: They receive folic acid powder 400 mg

Eligibility

Sex/Gender

Female

Age

20 Years to 38 Years

Inclusion criteria

Inclusion criteria: Women with polycystic ovary syndrome according to ESHRE-ASRM criteria Infertile women

Exclusion criteria

Exclusion criteria: Body mass index above 35 Endometriosis Azospermia Sever oligospermia Hydrosalpinx

Design outcomes

Primary

Measure	Time frame
The oocyte quality. Timepoint: Once, at the puncture day. Method of measurement: The embryologist reports.;The oocyte number. Timepoint: Once, at the puncture day. Method of measurement: The embryologist reports.;The embryo quality. Timepoint: Once, at the puncture day. Method of measurement: The embryologist reports.	—

Secondary

Measure	Time frame
Clinical pregnancy. Timepoint: Once, six weeks after fetal transfer. Method of measurement: Ultrasound.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFiroozeh Akbari Asbagh

Tehran University of Medical Sciences

fasbagh_md@yahoo.com+98 21 4216 0852

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026